Elucidata is hosting a panel with three experts on where I&I is making progress and what might shape the next generation of therapies.
Published
Signal category
Presence & Recognition
Quote
“So we are hosting a panel with three experts who do. Frédéric (Fred) Baribaud of Beeline Medicines, Hozefa Bandukwala, Ph.D. of Flagship Pioneering, and Sreeram Balasubramanian, PhD of Novasenta, on where I&I is actually making progress and what might shape the next generation of therapies.”
— Swetabh Pathak|Elucidata team
Company
Elucidata
The AI Partner Fueling 40+ FDA-Track Drugs
- Industry
- Software Development
- Location
- San Francisco, US
- Company size
- 170 employees
Recognized as Fast Company's Most Innovative Biotech Company of 2024. We are a data-driven, AI-powered biopharma solutions company that helps R&D teams move from 20,000 genes to the 2 targets worth a program's investment. We have partnered with 90+ biopharma companies and been part of 40 programs that have moved beyond IND. Our pipeline harmonizes 30+ data modalities like omics, assay, RWD, EHR etc. into a unified data model. LLM-powered curation with human-in-the-loop review delivers 99.99% data accuracy, 10x faster than manual workflows. This is backed by domain expertise that grounds every data product in biological context and direction which gives scientists a foundation they can act on with confidence. Our teams bring hands-on depth in core bioinformatics and plug in wherever needed: end-to-end discovery, infrastructure (knowledge graphs, Lens, MCP integration servers, co-scientists), curated multi-modal data, or methodology support. We also support patient stratification and in-silico validation bridged to wet-lab confirmation. Headquartered in San Francisco, with offices in Boston and India, we are a 120+ multidisciplinary team partnering with biopharma companies, CROs, academic institutions, and R&D teams worldwide.
Founded 2015